Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982;13(Suppl 1):87S–92S. doi: 10.1111/j.1365-2125.1982.tb01894.x

The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels

E Agabiti-Rosei, C L Alicandri, M Beschi, M Castellano, R Fariello, E Montini, M L Muiesan, G Romanelli, G Muiesan
PMCID: PMC1401846  PMID: 7093104

Abstract

1 Labetalol 100 mg was given intravenously to 27 patients with essential hypertension (12 males, 15 females; WHO I-II; age range 30-66 yr; on average, a significant reduction of blood pressure was observed within 5 min (P<0.001). Average heart rate was also reduced significantly (P<0.01).

2 In 18 patients haemodynamic measurements were performed (dye-dilution or thermodilution technique): blood pressure reduction was related to peripheral vasodilatation, as cardiac index remained unmodified.

3 The absolute and percentage decrease of blood pressure, heart rate and total peripheral resistance after labetalol 100 mg intravenously, was significantly greater in the patients with higher baseline plasma noradrenaline concentration values.

4 In 12 out of 27 patients labetalol was given orally for 2 months (dose range 300-1200 mg); the pattern of blood pressure and heart rate changes after oral therapy were comparable to those observed after acute administration of the drug.

5 The degree of blood pressure and heart rate reductions after oral labetalol was also significantly related to pretreatment basal noradrenaline concentration.

Full text

PDF
87S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agabiti-Rosei E., Alicandri C., Fariello R., Muiesan G. Catecholamines and haemodynamics in fixed essential hypertension. Clin Sci (Lond) 1979 Dec;57 (Suppl 5):193s–196s. doi: 10.1042/cs057193s. [DOI] [PubMed] [Google Scholar]
  2. Brecht H. M., Schoeppe W. Relation of plasma noradrenaline to blood pressure, age, sex and sodium balance in patients with stable essential hypertension and in normotensive subjects. Clin Sci Mol Med Suppl. 1978 Dec;4:81s–83s. doi: 10.1042/cs055081s. [DOI] [PubMed] [Google Scholar]
  3. Christensen N. J., Brandsborg O. The relationship between plasma catecholamine concentration and pulse rate during exercise and standing. Eur J Clin Invest. 1973 Jul;3(4):299–306. doi: 10.1111/j.1365-2362.1973.tb00355.x. [DOI] [PubMed] [Google Scholar]
  4. DeQuattro V., Chan S. Raised plasma-catecholamines in some patients with primary hypertension. Lancet. 1972 Apr 15;1(7755):806–809. doi: 10.1016/s0140-6736(72)90796-9. [DOI] [PubMed] [Google Scholar]
  5. Engelman K., Portnoy B., Sjoerdsma A. Catecholamines-cyclic amp-angiotensin receptors. Plasma catecholamine concentrations in patients with hypertension. Circ Res. 1970 Jul;27(1 Suppl 1):141–146. [PubMed] [Google Scholar]
  6. Jones D. H., Hamilton C. A., Reid J. L. Plasma noradrenaline, age and blood pressure: a population study. Clin Sci Mol Med Suppl. 1978 Dec;4:73s–75s. doi: 10.1042/cs055073s. [DOI] [PubMed] [Google Scholar]
  7. Kiowski W., Van Brummelen P., Bühler F. R. Plasma noradrenaline correlates with alpha-adrenoreceptor-mediated vasoconstriction and blood pressure in patients with essential hypertension. Clin Sci (Lond) 1979 Dec;57 (Suppl 5):177s–180s. doi: 10.1042/cs057177s. [DOI] [PubMed] [Google Scholar]
  8. Lake C. R., Ziegler M. G., Coleman M. D., Kopin I. J. Age-adjusted plasma norepinephrine levels are similar in normotensive and hypertensive subjects. N Engl J Med. 1977 Jan 27;296(4):208–209. doi: 10.1056/NEJM197701272960408. [DOI] [PubMed] [Google Scholar]
  9. Louis W. J., Doyle A. E., Anavekar S. Plasma norepinephrine levels in essential hyoertension. N Engl J Med. 1973 Mar 22;288(12):599–601. doi: 10.1056/NEJM197303222881203. [DOI] [PubMed] [Google Scholar]
  10. Mehta J., Cohn J. N. Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. Circulation. 1977 Feb;55(2):370–375. doi: 10.1161/01.cir.55.2.370. [DOI] [PubMed] [Google Scholar]
  11. Miura Y., Campese V., deQuattro V., Meijer D. Plasma catecholamines via an improved fluorimetric assay: comparison with an enzymatic method. J Lab Clin Med. 1977 Feb;89(2):421–427. [PubMed] [Google Scholar]
  12. Miura Y., Kobayashi K., Sakuma H., Tomioka H., Adachi M., Yoshinaga K. Plasma noradrenaline concentrations and haemodynamics in the early stage of essential hypertension. Clin Sci Mol Med Suppl. 1978 Dec;4:69s–71s. doi: 10.1042/cs055069s. [DOI] [PubMed] [Google Scholar]
  13. Prichard B. N., Thompson F. O., Boakes A. J., Joekes A. M. Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension. Clin Sci Mol Med Suppl. 1975 Jun;2:97s–100s. doi: 10.1042/cs048097s. [DOI] [PubMed] [Google Scholar]
  14. Renzini V., Brunori C. A., Valori C. A sensitive and specific fluorimetric method for the determination of noradrenalin and adrenalin in human plasma. Clin Chim Acta. 1970 Dec;30(3):587–594. doi: 10.1016/0009-8981(70)90249-4. [DOI] [PubMed] [Google Scholar]
  15. Rosei E. A., Trust P. M., Brown J. J., Lever A. F., Robertson J. I. Letter: Intravenous labetalol in severe hypertension. Lancet. 1975 Nov 29;2(7944):1093–1094. doi: 10.1016/s0140-6736(75)90470-5. [DOI] [PubMed] [Google Scholar]
  16. Von Euler U. S. Sympatho-adrenal activity inphysical exercise. Med Sci Sports. 1974 Fall;6(3):165–173. [PubMed] [Google Scholar]
  17. de Champlain J., Farley L., Cousineau D., van Ameringen M. R. Circulating catecholamine levels in human and experimental hypertension. Circ Res. 1976 Feb;38(2):109–114. doi: 10.1161/01.res.38.2.109. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES